Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 526

1.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Sep 6;73:51-57. doi: 10.1016/j.leukres.2018.08.022. [Epub ahead of print]

2.

Molecular pathogenesis of disease progression in MLL-rearranged AML.

Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H.

Leukemia. 2018 Sep 12. doi: 10.1038/s41375-018-0253-3. [Epub ahead of print]

PMID:
30209403
3.

Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses.

Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF.

Oncogene. 2018 Aug 23. doi: 10.1038/s41388-018-0455-1. [Epub ahead of print]

PMID:
30140044
4.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK.

Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7. doi: 10.1016/j.leukres.2018.07.016. [Epub ahead of print]

PMID:
30055822
5.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

6.

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y.

J Clin Invest. 2018 Aug 27. pii: 97117. doi: 10.1172/JCI97117. [Epub ahead of print]

7.

Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC).

Chu Y, Zhao Z, Sant DW, Zhu G, Greenblatt SM, Liu L, Wang J, Cao Z, Tho JC, Chen S, Liu X, Zhang P, Maciejewski JP, Nimer S, Wang G, Yuan W, Yang FC, Xu M.

Genomics Proteomics Bioinformatics. 2018 Jun;16(3):172-186. doi: 10.1016/j.gpb.2018.04.005. Epub 2018 Jun 13.

8.

Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.

Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumbreras E, Przychodzen B, Caparros E, Amigo ML, Dıez-Campelo M, Zamora L, Salido Fierrez EJ, Maciejewski JP, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marin F, Wiseman DH, Jerez A.

Br J Haematol. 2018 May 24. doi: 10.1111/bjh.15408. [Epub ahead of print]

PMID:
29797327
9.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
10.

Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria.

Clemente MJ, Przychodzen B, Hirsch CM, Nagata Y, Bat T, Wlodarski MW, Radivoyevitch T, Makishima H, Maciejewski JP.

Leukemia. 2018 Apr 25. doi: 10.1038/s41375-018-0138-5. [Epub ahead of print] No abstract available.

PMID:
29749402
11.

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1889-1892. doi: 10.1200/JCO.2018.78.4074. Epub 2018 May 3. No abstract available.

PMID:
29723096
12.

Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, Maciejewski J, Yi Q, Zhao JJ.

Leukemia. 2018 Mar 22. doi: 10.1038/s41375-018-0104-2. [Epub ahead of print]

PMID:
29632340
13.

Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus.

Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI.

Eur J Haematol. 2018 Jul;101(1):3-11. doi: 10.1111/ejh.13059. Epub 2018 May 16.

PMID:
29532535
14.

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML.

Przychodzen B, Makishima H, Sekeres MA, Balasubramanian SK, Thota S, Patel BJ, Clemente M, Hirsch C, Dienes B, Maciejewski JP.

Oncotarget. 2017 Dec 16;9(2):2050-2057. doi: 10.18632/oncotarget.23328. eCollection 2018 Jan 5.

15.

Wild-type and mutated IDH1/2 enzymes and therapy responses.

Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF.

Oncogene. 2018 Apr;37(15):1949-1960. doi: 10.1038/s41388-017-0077-z. Epub 2018 Jan 25. Review. Erratum in: Oncogene. 2018 Aug 23;:.

16.

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.

Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, van Noorden CJF, Maciejewski JP.

Clin Cancer Res. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16.

PMID:
29339439
17.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

18.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
19.

Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age.

Maciejewski JP, Balasubramanian SK.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):66-72. doi: 10.1182/asheducation-2017.1.66. Review.

PMID:
29222238
20.

Rational management approach to pure red cell aplasia.

Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP.

Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.

21.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
22.

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.

Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway HE, Sekeres MA, Radivoyevitch T, Yoshida K, Sanada M, Yoshizato T, Kataoka K, Nakagawa MM, Ueno H, Nannya Y, Kon A, Shiozawa Y, Takeda J, Shiraishi Y, Chiba K, Miyano S, Singh J, Padgett RA, Ogawa S, Maciejewski JP, Makishima H.

Leukemia. 2018 Mar;32(3):839-843. doi: 10.1038/leu.2017.319. Epub 2017 Nov 3. No abstract available.

PMID:
29099495
23.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski J, Auberger P, Wei S, Fenaux P, Santini V, List A.

Haematologica. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5.

24.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22. No abstract available.

PMID:
28935992
25.

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP.

Br J Haematol. 2017 Sep 14. doi: 10.1111/bjh.14907. [Epub ahead of print] No abstract available.

PMID:
28905372
26.

Origins of myelodysplastic syndromes after aplastic anemia.

Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C, Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, Maciejewski JP.

Blood. 2017 Oct 26;130(17):1953-1957. doi: 10.1182/blood-2017-02-767731. Epub 2017 Sep 11. No abstract available.

PMID:
28893734
27.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2017 Sep 1;7(9):e602. doi: 10.1038/bcj.2017.82. No abstract available.

28.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18. No abstract available.

PMID:
28819282
29.

The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy.

Bat T, Abdelhamid ON, Balasubramanian SK, Mai A, Radivoyevitch T, Clemente M, Maciejewski JP.

Br J Haematol. 2018 Sep;182(5):730-733. doi: 10.1111/bjh.14862. Epub 2017 Aug 14. No abstract available.

PMID:
28804905
30.

GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.

Enane FO, Shuen WH, Gu X, Quteba E, Przychodzen B, Makishima H, Bodo J, Ng J, Chee CL, Ba R, Seng Koh L, Lim J, Cheong R, Teo M, Hu Z, Ng KP, Maciejewski J, Radivoyevitch T, Chung A, Ooi LL, Tan YM, Cheow PC, Chow P, Chan CY, Lim KH, Yerian L, Hsi E, Toh HC, Saunthararajah Y.

J Clin Invest. 2017 Sep 1;127(9):3527-3542. doi: 10.1172/JCI93488. Epub 2017 Jul 31.

31.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
32.

DDX41-related myeloid neoplasia.

Maciejewski JP, Padgett RA, Brown AL, Müller-Tidow C.

Semin Hematol. 2017 Apr;54(2):94-97. doi: 10.1053/j.seminhematol.2017.04.007. Epub 2017 Apr 21. Review.

PMID:
28637623
33.

Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).

Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C, Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, Maciejewski JP.

Leuk Lymphoma. 2018 Feb;59(2):416-422. doi: 10.1080/10428194.2017.1339880. Epub 2017 Jun 20.

PMID:
28633612
34.

Genomic determinants of chronic myelomonocytic leukemia.

Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP.

Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30.

PMID:
28555081
35.

Photochromic Torsional Switch (PTS): a light-driven actuator for the dynamic tuning of π-conjugation extension.

Maciejewski J, Sobczuk A, Claveau A, Nicolai A, Petraglia R, Cervini L, Baudat E, Miéville P, Fazzi D, Corminboeuf C, Sforazzini G.

Chem Sci. 2017 Jan 1;8(1):361-365. doi: 10.1039/c6sc03196j. Epub 2016 Aug 16.

36.

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.

Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, Maciejewski JP, Yang FC, Jin P, Xu M.

Nat Commun. 2017 Apr 25;8:15102. doi: 10.1038/ncomms15102.

37.

Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome.

Varney ME, Choi K, Bolanos L, Christie S, Fang J, Grimes HL, Maciejewski JP, Inoue JI, Starczynowski DT.

Leukemia. 2017 Jul;31(7):1659. doi: 10.1038/leu.2017.95. Epub 2017 Apr 7.

38.

Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches.

Hira VVV, Van Noorden CJF, Carraway HE, Maciejewski JP, Molenaar RJ.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):183-198. doi: 10.1016/j.bbcan.2017.03.010. Epub 2017 Mar 28. Review.

39.

Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salamonis N, Geiger H, Zheng Y, Starczynowski DT.

Nat Immunol. 2017 Mar 22;18(4):474. doi: 10.1038/ni0417-474a. No abstract available.

40.

Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).

Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ.

Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.

PMID:
28318095
41.

Molecular features of early onset adult myelodysplastic syndrome.

Hirsch CM, Przychodzen BP, Radivoyevitch T, Patel B, Thota S, Clemente MJ, Nagata Y, LaFramboise T, Carraway HE, Nazha A, Sekeres MA, Makishima H, Maciejewski JP.

Haematologica. 2017 Jun;102(6):1028-1034. doi: 10.3324/haematol.2016.159772. Epub 2017 Mar 2.

42.

A myeloid tumor suppressor role for NOL3.

Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.

J Exp Med. 2017 Mar 6;214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23.

43.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Suzuki H, Nagata Y, Sato Y, Kakiuchi N, Matsuo K, Onizuka M, Kataoka K, Chiba K, Tanaka H, Ueno H, Nakagawa MM, Przychodzen B, Haferlach C, Kern W, Aoki K, Itonaga H, Kanda Y, Sekeres MA, Maciejewski JP, Haferlach T, Miyazaki Y, Horibe K, Sanada M, Miyano S, Makishima H, Ogawa S.

Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.

44.

Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach.

Coppe A, Andersson EI, Binatti A, Gasparini VR, Bortoluzzi S, Clemente M, Herling M, Maciejewski J, Mustjoki S, Bortoluzzi S.

Leukemia. 2017 May;31(5):1243-1246. doi: 10.1038/leu.2017.49. Epub 2017 Feb 7. No abstract available.

45.

Deletion of Ptpn1 induces myeloproliferative neoplasm.

Jobe F, Patel B, Kuzmanovic T, Makishima H, Yang Y, Przychodzen B, Hutchison RE, Bence KK, Maciejewski JP, Mohi G.

Leukemia. 2017 May;31(5):1229-1234. doi: 10.1038/leu.2017.31. Epub 2017 Jan 23. No abstract available.

46.

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.

47.

Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salomonis N, Geiger H, Zheng Y, Starczynowski DT.

Nat Immunol. 2017 Feb;18(2):236-245. doi: 10.1038/ni.3654. Epub 2016 Dec 26. Erratum in: Nat Immunol. 2017 Mar 22;18(4):474.

48.

Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

PMID:
27992414
49.

The complexity of interpreting genomic data in patients with acute myeloid leukemia.

Nazha A, Zarzour A, Al-Issa K, Radivoyevitch T, Carraway HE, Hirsch CM, Przychodzen B, Patel BJ, Clemente M, Sanikommu SR, Kalaycio M, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2016 Dec 16;6(12):e510. doi: 10.1038/bcj.2016.115.

50.

Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.

Nguyen N, Vishwakarma BA, Oakley K, Han Y, Przychodzen B, Maciejewski JP, Du Y.

Oncotarget. 2016 Dec 27;7(52):86300-86312. doi: 10.18632/oncotarget.13383.

Supplemental Content

Loading ...
Support Center